Aprea therapeutics provides clinical update from acesot-1051 trial showing early signals of activity for wee1 kinase inhibitor apr-1051

Doylestown, pa., oct. 24, 2025 (globe newswire) -- aprea therapeutics, inc. (nasdaq: apre) (“aprea”, or the “company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on the ongoing phase 1 acesot-1051 (a multi-center evaluation of wee1 inhibitor in patients with advanced solid tumors, apr-1051) study. the latest results show that, at the 100 mg apr-1051 dose level, 3 out of 4 patients achieved stable disease, as measured using recist v1.1 criteria.
APR Ratings Summary
APR Quant Ranking